Worrall N K, Lazenby W D, Misko T P, Lin T S, Rodi C P, Manning P T, Tilton R G, Williamson J R, Ferguson T B
Department of Surgery (Division of Cardiothoracic Surgery), Washington University School of Medicine, Saint Louis, Missouri 63110.
J Exp Med. 1995 Jan 1;181(1):63-70. doi: 10.1084/jem.181.1.63.
The role of nitric oxide in the immune response to allogeneic tissue was explored in an in vivo cardiac transplant model in the rat. Nitric oxide production during organ rejection was demonstrated by elevations in systemic serum nitrite/nitrate levels and by electron paramagnetic resonance spectroscopy. Messenger RNA for the inducible nitric oxide synthase enzyme was detected in the rejecting allografted heart, but not in the nonrejecting isografted heart. The enzyme was demonstrated to be biologically active by the in vitro conversion of L-arginine to L-citrulline and was immunohistochemically localized to the infiltrating inflammatory cells. Treatment with aminoguanidine, a preferential inhibitor of the inducible nitric oxide synthase isoform, prevented the increased nitric oxide production in the transplanted organ and significantly attenuated the pathogenesis of acute rejection. Aminoguanidine treatment prolonged graft survival, improved graft contractile function, and significantly reduced the histologic grade of rejection. These results suggest an important role for nitric oxide in mediating the immune response to allogeneic tissue. Inhibition of inducible nitric oxide synthase may provide a novel therapeutic modality in the management of acute transplant rejection and of other immune-mediated processes.
在大鼠体内心脏移植模型中探究了一氧化氮在同种异体组织免疫反应中的作用。通过全身血清亚硝酸盐/硝酸盐水平升高以及电子顺磁共振光谱法证实了器官排斥反应期间一氧化氮的产生。在发生排斥反应的同种异体移植心脏中检测到诱导型一氧化氮合酶的信使核糖核酸,而在未发生排斥反应的同基因移植心脏中未检测到。通过L-精氨酸体外转化为L-瓜氨酸证明该酶具有生物活性,并且通过免疫组织化学定位到浸润的炎性细胞。用氨基胍(诱导型一氧化氮合酶同工型的优先抑制剂)进行治疗,可防止移植器官中一氧化氮产生增加,并显著减轻急性排斥反应的发病机制。氨基胍治疗可延长移植物存活时间,改善移植物收缩功能,并显著降低排斥反应的组织学分级。这些结果表明一氧化氮在介导同种异体组织免疫反应中起重要作用。抑制诱导型一氧化氮合酶可能为急性移植排斥反应和其他免疫介导过程的管理提供一种新的治疗方式。